Worldwide News

European Pharmacopoeia (Ph. Eur.) General Chapter 2.1.7 Balances for Analytical Purposes was published in July 2021. Compliance with this chapter by January 1, 2022 is mandatory for any pharmaceutical company who manufactures in, or exports into, the European market.   Balances for Analytical Purposes aims to ensure quality control of medicines in European member states. The requirements of Ph. Eur. are similar […]

A Phase I clinical trial of the world’s first multivariant Covid-19 vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester UK and Manchester University NHS Foundation Trust.  Initially involving participants aged 60+, its creators say the drug, GRT-R910, can boost the immune response of first-generation Covid-19 vaccines to […]

Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia.  Currently, there are no treatments on the market for cognitive impairment associated with schizophrenia, despite efforts by pharmaceutical companies over the last decade. One of the recognised limitations of previous […]

News round-up by DDW’s Megan Thomas for 13-17 September  The news in the drug discovery industry this week has demonstrated the potential that remains untapped for a number of industries at large as well as taking early steps towards future cures and treatments. DDW’s Megan Thomas has rounded up five stories which showcase this breakthrough […]

Registration for SLAS 2022 International Conference and Exhibition is available for in-person attendance in Boston or the online digital experience, with the option to change online or in-person status later.   Abstract submission is still open and applicants can choose to present in-person or online. Student Poster Awards and Tony B Academic Travel Awards are also […]

Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.  Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and schizophrenia. Current treatment options for memory loss are […]

Illumina and Merck have partnered to develop and commercialise tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD).   Patients whose tumours are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina’s TruSight Oncology 500 (TSO 500) content, enabling genomic profiling assays in a […]

Swedish company Gedea Biotech has announced that it has enrolled more than 50% of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomised double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by Nottingham University NHS Hospitals Trust in the UK.  […]

New analysis suggests that the Moderna Covid-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the US Centers for Disease Control and Prevention (CDC).   Additionally, the company shared a new analysis of follow-up through one year in […]

If you are interested in understanding how to optimise analytical methods to accelerate biosimilar development, register for this exclusive DDW event, supported by Bio-Techne. Using an automated CE-SDS platform in efficient biosimilar comparability studies is on 29 September at 4PM BST.  Register here for this free, virtual event. In this webinar, Dr. Richard L. Easton, Technical Director of Structural Analysis […]